AM
Amrutanjan Health Care Ltd (AMRUTANJAN)
₹512.65
Mkt cap
₹1,482 Cr
P/E ratio
22.60
P/B
3.85
Div yield
0.96%
ROE
18.40%
ROCE
24.80%
EPS (TTM)
₹22.68
Book value
₹133
52W range
477–726
Sector
Healthcare
Price history
Previous close
AHCL has been manufacturing ayurvedic balm for pain management since 1893, and is currently managed by the third-generation of promoters. The company is more than 120 years old and is into OTC products in the segments of pain management, women's hygiene, and packaged fruit juice drink. [1]
NSE AMRUTANJANBSE 590006
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsBearish
52-week range
−29.35% from high₹513
₹477+7.59% from low₹726
Current
₹512.65
Prev close
₹517.05
Day
−0.85%
Price performance
1D
−0.49%
1W
+1.19%
1M
+3.52%
3M
−1.37%
6M
−6.33%
1Y
−28.53%
YTD
−23.80%
Financials
Revenue, profit & margin
P/E ratio
22.6×
AMRUTANJAN is 30% below the sector median of 32.5×
AMRUTANJAN22.6×
Sector median32.5×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 99 | 117 | 127 | 84 | 110 | 123 | 135 | 94 | 118 | 141 | 150 | 103 | 135 | |
| YoY Sales growth | -10% | +20% | +27% | +8% | +11% | +5% | +7% | +12% | +7% | +15% | +11% | +9% | +15% | |
| Expenses | 92 | 95 | 111 | 80 | 96 | 99 | 118 | 86 | 101 | 116 | 124 | 97 | 112 | |
| Operating Profit | 7 | 22 | 16 | 4 | 14 | 23 | 18 | 8 | 17 | 25 | 26 | 6 | 24 | |
| OPM % | 7% | 18% | 13% | 4.2% | 12% | 19% | 13% | 9% | 14% | 18% | 17% | 6% | 17% | |
| Other Income | 4 | 4 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 3 | -3 | 2 | 3 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | |
| Profit before tax | 9 | 24 | 20 | 6 | 16 | 26 | 21 | 11 | 19 | 26 | 21 | 6 | 23 | |
| Tax % | 26% | 26% | 30% | 27% | 26% | 26% | 27% | 26% | 27% | 26% | 23% | 28% | 25% | |
| Net Profit | 7 | 17 | 14 | 5 | 12 | 19 | 15 | 8 | 14 | 19 | 16 | 4 | 17 | |
| EPS in Rs | 2.37 | 6.04 | 4.72 | 1.60 | 4.08 | 6.66 | 5.25 | 2.87 | 4.83 | 6.73 | 5.60 | 1.51 | 5.98 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Interim Dividend - Re 1 Per Share | — | 6 Nov '26 | 7 Nov '26 |
Shareholding
as of Sep 202646.52%Promoter
Promoters46.52%
FIIs3.47%1.03
DIIs6.90%5.39
Public43.08%4.36
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,884.90 | 36.76 | 4,52,251 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,180.50 | 86.86 | 2,96,807 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,689.50 | 82.16 | 1,78,374 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,294.60 | 92.53 | 1,23,980 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,200.00 | 26.42 | 1,19,700 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,390.20 | 41.47 | 1,16,119 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,415.00 | 36.81 | 1,14,316 | 0.92% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Amrutanjan Healt | ₹512.65 | 22.62 | 1,482 | 0.96% | 17 | +23.78% | 135 | +14.85% | 24.84% |
| Median: 160 Co. | ₹432.20 | 32.47 | 1,983 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports15
Concall transcripts33
Credit ratings6
Announcements5
Investor Presentation For The Quarter Ended 30Th September 2026 3 NovRecord Date For The First Interim Dividend 2026-27 3 Nov - Record date fixed as 7 November 2026 for 1st interim dividend FY2026-27.Board Meeting Outcome for Outcome For The Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026 3 Nov - Board approved Q2 FY27 results and declared Re.1 interim dividend per share.Board Meeting Intimation for Unaudited Financial Results For The Quarter And Half Year Ended 30Th September 2026
Declaration Of 1St Interim Dividend 2026-2027 27 Oct - Board meets on 3 Nov 2026 to approve Q2 results and consider first interim dividend.Intimation Of ESG Ratings 9 Oct - CRISIL independently rated Amrutanjan Health Care ESG as 'Adequate' with score 60.






